Michael T. Yin, MD

Dr. Michael Yin is an infectious disease specialist who has dedicated his career towards optimizing HIV treatment and prevention. His research focuses upon non-infectious complications of HIV which is growing in significance as people with HIV live longer with effective antiretroviral therapy (ART) and experience accentuated aging-related complications. He has evaluated the epidemiology and pathogenic mechanisms of HIV associated bone loss in postmenopausal women, adolescents, and children with perinatal infection. Using novel imaging techniques and translational bone cell assays, he has made important discoveries about the dysregulation of bone metabolism associated with HIV infection and ART and investigated therapeutic strategies to mitigate bone loss and fracture. In addition to skeletal complications, Dr. Yin has also studied the impact of HIV and ART on cardiovascular disease, metabolic syndrome, obesity, frailty and falls. Recent work has extended to evaluation of epigenetic aging in children, adolescents and adults living with HIV.

Much of Dr. Yin’s research builds upon interdisciplinary collaborations within HIV networks. He is an active investigator in AIDS Clinical Trials Group (ACTG) and the Combined Cohort Study (MACS/WIHS). Dr. Yin has also led studies to engage hard to reach populations both for HIV prevention and treatment, using combinations of behavioral, structural and biomedical strategies. These multidisciplinary efforts have relied upon collaboration with colleagues with expertise in behavioral science, implementation science and biomedical informatics. He is the Co-Director of the Clinical Translation Core of the HIV Center for Clinical and Behavioral Studies, New York State Psychiatric Institute and Columbia University. His team has also been immersed in COVID-19 research and established a longitudinal cohort, the COVID-19 Persistence ID Cohort (C-PIC), to study viral dynamics, evolution of antibody response and the post-acute sequelae of SARS-CoV-2 (PASC) in collaboration with researchers at the Aaron Diamond AIDS Research Center (ADARC).